Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Schnittger

Showing results (71-80 of 131) with videos related to

Pageof 14
Sort By:
Leukemia|May 1, 2013
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutationsM Meggendorfer, U Bacher, T Alpermann, et al.
Leukemia|February 13, 2002
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 casesC Schoch, S Schnittger, S Bursch, et al.
Leukemia|October 10, 2008
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotypeF Dicker, H Herholz, S Schnittger, et al.
British Journal of Haematology|August 30, 2006
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETOF Kuchenbauer, S Schnittger, T Look, et al.
Leukemia|February 23, 2011
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevanceV Grossmann, A Kohlmann, C Eder, et al.
Blood Cancer Journal|September 4, 2012
Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myelomaV Grossmann, U Bacher, V Artusi, et al.
Leukemia|July 21, 2012
GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosisA Fasan, C Eder, C Haferlach, et al.
British Journal of Haematology|July 10, 2001
Low frequency of reverse transcription polymerase chain reaction-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual diseaseV H van der Velden, C Schoch, A W Langerak, et al.
Leukemia|January 10, 2014
High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcomeM-T Krauth, C Eder, T Alpermann, et al.
Leukemia|April 16, 2011
Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristicsU Bacher, W Kern, T Alpermann, et al.
Pageof 14

Showing results (71-80 of 131) with videos related to

Sort By:
Pageof 14
Leukemia|May 1, 2013
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutationsM Meggendorfer, U Bacher, T Alpermann, et al.
Leukemia|February 13, 2002
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 casesC Schoch, S Schnittger, S Bursch, et al.
Leukemia|October 10, 2008
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotypeF Dicker, H Herholz, S Schnittger, et al.
British Journal of Haematology|August 30, 2006
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETOF Kuchenbauer, S Schnittger, T Look, et al.
Leukemia|February 23, 2011
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevanceV Grossmann, A Kohlmann, C Eder, et al.
Blood Cancer Journal|September 4, 2012
Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myelomaV Grossmann, U Bacher, V Artusi, et al.
Leukemia|July 21, 2012
GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosisA Fasan, C Eder, C Haferlach, et al.
British Journal of Haematology|July 10, 2001
Low frequency of reverse transcription polymerase chain reaction-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual diseaseV H van der Velden, C Schoch, A W Langerak, et al.
Leukemia|January 10, 2014
High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcomeM-T Krauth, C Eder, T Alpermann, et al.
Leukemia|April 16, 2011
Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristicsU Bacher, W Kern, T Alpermann, et al.
Pageof 14